Dry eye disease is a multifactorial syndrome, characterized by symptoms of dryness and irritation of the ocular surface due to alteration in the quality or quantity of tear film.
It has been estimated that between 5 percent and 50 percent of the population at different ages suffer from DED making it one of the most common ocular conditions.
At the time of writing, there is neither a definite cure, nor effective treatment for severe forms of DED. The endogenous tear glycoprotein lacritin is currently viewed as perhaps the most promising approach to treatment of major forms of DED.
Lacritin is mainly secreted by the meibomian gland, but also by epithelial cells of the conjunctiva and cornea. The multifunctional role of lacritin has raised the possibility of its useful clinical application for topical treatment of DED if efficient and safe delivery systems can be developed.
This undertaking forms the main theme of the ongoing project.